# GLOW Blend (BPC-157 + TB-500 + GHK-Cu)

> The GLOW blend is a supplier-defined research formulation that combines three tissue-repair peptides: BPC-157, a synthetic 15-amino-acid gastric peptide; TB-500, a name associated with thymosin beta-4; and GHK-Cu, the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It is not an approved or standardized product, and no published study has examined the three-peptide combination.

Canonical: https://peptideproperties.com/compounds/glow-blend/

## Identity

- **Class:** Tissue-Repair Peptides

## Key facts

- Components: BPC-157, TB-500 (thymosin beta-4 or a fragment) and GHK-Cu (copper tripeptide-1)
- "GLOW" is a supplier name, not a scientific or regulatory designation
- Commonly supplied as a 70 mg vial, listed by some suppliers as 50/10/10 mg
- Molecular weights: BPC-157 1419.5 g/mol; thymosin beta-4 4963 g/mol; GHK-Cu 402.92 g/mol
- No published study of the three-peptide combination was found
- Regulatory status: none of the components is an FDA-approved drug

## What Is the GLOW Blend?

The GLOW blend is a supplier-defined combination of three research peptides: BPC-157, TB-500 and GHK-Cu. "GLOW" is a name used by suppliers, not a scientific or regulatory designation, and the blend is neither an approved drug nor a product with a standardized composition.It is commonly supplied as a 70 mg vial, and some suppliers list the contents as 50/10/10 mg. Because each supplier sets the ratio, the label and certificate of analysis should state which amount corresponds to which peptide; the blend name alone does not define it.The three components come from different bodies of research. BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and studied across numerous animal models.[1] TB-500 is a name usually associated with thymosin beta-4 (Tβ4), a 43-residue peptide, although a 2026 review in Sports Medicine describes TB-500 as a thymosin beta-4 fragment.[2] GHK-Cu is the copper complex of GHK (glycyl-L-histidyl-L-lysine), a tripeptide present in human plasma, saliva and urine that declines with age; it is also known by the cosmetic name copper tripeptide-1.[3]

## Components at a Glance

The blend combines peptides of very different sizes, from a three-residue copper complex to a 43-residue protein fragment, each with its own primary mechanism in the literature.ComponentClassPrimary target or mechanism studiedMolecular weightBPC-157Synthetic 15-amino-acid gastric peptide (C62H98N16O22)VEGFR2 activation, nitric oxide synthesis via the Akt-eNOS axis, and ERK1/2 signaling[1]1419.5 g/molTB-500 (thymosin beta-4)Beta-thymosin peptide, 43 residues, N-terminally acetylated (C212H350N56O78S)Binding and sequestering monomeric G-actin[4]4963 g/mol (full-length Tβ4)GHK-CuCopper(II) complex of a tripeptide; cosmetic ingredient (C14H23CuN6O4+)Synthesis and breakdown of collagen and glycosaminoglycans; modulation of metalloproteinases and their inhibitors[3]402.92 g/molThe TB-500 figure is for full-length thymosin beta-4 (PubChem CID 45382195); a fragment would weigh far less. Salt forms of any component also change the mass of the bulk material.

## Why These Compounds Are Studied Together

The three peptides share a research theme, tissue repair, but no published study has tested them as a combination or shown that they interact. Evidence for the blend comes entirely from separate studies of each component, which differ in focus and in the strength of their data.
### A shared tissue-repair theme
A 2026 orthopedic review groups BPC-157, TB-500 and GHK-Cu as wound-healing peptides that promote angiogenesis, integrin-mediated extracellular matrix remodeling and fibroblast activation.[5] A 2026 primer for orthopedic and sports medicine physicians reviewed the same three peptides among the most popular types of injectable peptide therapy and concluded that evidence supporting their clinical use is currently lacking.[6]
### Different research focus for each component

- BPC-157: musculoskeletal models. A 2025 systematic review reported improved functional, structural and biomechanical outcomes in rodent muscle, tendon, ligament and bone injuries.[7]
- Thymosin beta-4: cardiac and eye research. It reduced infarct volume and increased blood vessel growth in preclinical cardiac ischemia models,[8] and Tβ4 eye drops reached phase 3 trials for dry eye and neurotrophic keratopathy.[9]
- GHK-Cu: skin and connective tissue. Reviews describe increased collagen, elastin and glycosaminoglycan synthesis and support of dermal fibroblast function,[10] and GHK-Cu is widely used in anti-wrinkle products.[11] In a rat anterior cruciate ligament reconstruction model, it improved knee laxity and graft stiffness at 6 weeks, but the differences were gone by 12 weeks.[12]
### What the combination literature shows
No study of the three-peptide combination was found. The only data on any pairing within the blend come from a retrospective knee pain chart review in which 4 patients received both BPC-157 and thymosin beta-4; 3 of the 4 reported significant improvement, with no control group or standardized outcome measures.[13] GHK-Cu was not part of that review. Claims that the three components work synergistically are not supported by published data.With three peptides and supplier-set ratios, researchers look for HPLC and mass spectrometry data that confirm each component's identity and stated amount.

## Research Status

The GLOW blend is not an approved product, and none of its components is an FDA-approved drug. BPC-157 has not been approved by the FDA or other regulators because sufficient human clinical studies are lacking,[14] and GHK-Cu is used commercially as a cosmetic ingredient rather than a drug.[11]Human evidence is thin for all three components. The 2025 systematic review of BPC-157 included 36 studies, 35 of them preclinical, rated at evidence levels IV and V.[7] The 2026 physician primer found that human orthopedic data for thymosin beta-4 and TB-500 are lacking, that no clinical data support GHK-Cu for musculoskeletal conditions, and that indications and treatment parameters for these peptides remain unknown.[6] A review of topical GHK products noted a surprising absence of clinical studies even in cosmetic use.[11]A 2026 review in Sports Medicine lists BPC-157, GHK-Cu, Tβ4 and TB-500 among peptides marketed directly to patients through a gray market largely outside regulatory oversight, and notes that rigorous human safety data are scarce, with potential for serious harm.[2] The physician primer also reports that thymosin beta-4 and TB-500 remain banned substances in sports.[6] The blend is sold for laboratory research use only, and each component's evidence should be read on its own terms.

## FAQ

**What is in the GLOW blend?**
The GLOW blend contains three peptides: BPC-157, a synthetic 15-amino-acid gastric peptide; TB-500, a name associated with thymosin beta-4; and GHK-Cu, the copper complex of the tripeptide GHK. It is commonly supplied as a 70 mg vial, listed by some suppliers as 50/10/10 mg. It is not a standardized formulation, so the label should state each amount.

**Has the GLOW blend been studied?**
No published study of the three-peptide combination was found. Evidence comes from separate, mostly preclinical studies of BPC-157, thymosin beta-4 and GHK-Cu. The only data on any pairing within the blend is a small retrospective knee pain chart review in which 4 patients received BPC-157 and thymosin beta-4 together, without a control group.

**Is GLOW the same as KLOW?**
No. Both are supplier-defined blends built on BPC-157, TB-500 and GHK-Cu, but KLOW adds a fourth peptide, KPV. Neither blend is standardized, so the components and amounts depend on the individual supplier's label and certificate of analysis. Neither combination has been studied as a whole in published research.

**Why is GHK-Cu combined with BPC-157 and TB-500?**
No published study explains or tests this specific pairing. A 2026 orthopedic review groups all three as wound-healing peptides associated with angiogenesis, extracellular matrix remodeling and fibroblast activation. GHK-Cu is best known from skin and connective tissue research and is widely used as the cosmetic ingredient copper tripeptide-1.

**Is the GLOW blend FDA approved?**
No. None of its components is an FDA-approved drug, and the blend has no approved or standardized form. A 2026 Sports Medicine review lists BPC-157, GHK-Cu, thymosin beta-4 and TB-500 among unapproved peptides sold largely outside regulatory oversight, and notes that rigorous human safety data are scarce.

## References

1. McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine 2025. PMID: 40789979
2. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.) 2026. PMID: 41966639
3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed research international 2015. PMID: 26236730
4. Hannappel E. beta-Thymosins. Annals of the New York Academy of Sciences 2007. PMID: 17468232
5. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews 2026. PMID: 41490200
6. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine 2026. PMID: 41476424
7. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery 2025. PMID: 40756949
8. Pipes GT, Yang J. Cardioprotection by Thymosin Beta 4. Vitamins and hormones 2016. PMID: 27450736
9. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert opinion on biological therapy 2018. PMID: 30063853
10. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International journal of molecular sciences 2018. PMID: 29986520
11. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts : BI 2025. PMID: 39963574
12. Fu SC, Cheuk YC, Chiu WY, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2015. PMID: 25731775
13. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine 2021. PMID: 34324435
14. Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland) 2025. PMID: 40005999